Braidwell »

Hemab Therapeutics Holdings shares owned by Braidwell

Quarter-by-quarter ownership of Hemab Therapeutics Holdings shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Hemab Therapeutics Holdings

Tip: Access up to 7 years of quarterly data

All positions including Hemab Therapeutics Holdings held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Hemab Therapeutics Holdings by Braidwell

Quarter filed Position value Share count Share price at filing
2026-06-30 $5.9M 160k 36.73

More positions owned by Braidwell

Caris Life Sciences (CAI)
Hinge Health Cl A (HNGE)
Glaukos (GKOS)
Edgewise Therapeutics (EWTX)
Spyre Therapeutics Com New (SYRE)
Irhythm Technologies (IRTC)
Neogenomics Com New (NEO)
Kodiak Sciences (KOD)
Xenon Pharmaceuticals (XENE)
Alphatec Hldgs Note 0.750% 3/1 (Principal)
Monte Rosa Therapeutics (GLUE)
Dianthus Therapeutics (DNTH)
Neurocrine Biosciences (NBIX)
Alphatec Hldgs Com New (ATEC)
Generate Biomedicines Com Shs (GENB)

View all positions for Braidwell

Top funds holding Hemab Therapeutics Holdings

RA Capital Management
Novo A/S
Jpmorgan Chase & Co
Vanguard Capital Management
Citadel Advisors
Braidwell
Marshall Wace
Affinity Asset Advisors
Vanguard Fiduciary Trust
Burkehill Global Management
Standard Life Aberdeen
TD Asset Management
GSA Capital Partners
Schonfeld Strategic Advisors
Vanguard Portfolio Management

View all funds holding Hemab Therapeutics Holdings